Continuous glucose monitoring with Humalog Mix 25 versus Humalog Mix 50, twice daily: A comparative pilot study -Results from the Jikei-EValuation of insulin Lispro mixture on pharmacodynamics and glycemic VariancE (J-EVOLVE) study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Nishimura, Rimei ^a   Tsujino, Daisuke ^a   Taki, Kentaro ^a   Morimoto, Aya ^a   Tajima, Naoko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HUMALOG MIX 25; HUMALOG MIX 50; INSULIN LISPRO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HUMALOG MIX25; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG FORMULATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PILOT STUDY; TREATMENT OUTCOME; AMBULATORY MONITORING; ASIAN; BLOOD; CALORIC INTAKE; COMPARATIVE STUDY; DRUG ADMINISTRATION; ETHNOLOGY; JAPAN; METABOLISM; MIDDLE AGED; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; ENERGY INTAKE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PILOT PROJECTS; POSTPRANDIAL PERIOD; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955706306     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-16     Document Type: Article

References (13)

1. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. 10.1056/NEJM199309303291401, 8366922, 8366922 , The Diabetes Control and Complications Trial Research Group .
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117. 10.1016/0168-8227(95)01064-K, 7587918.
3. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007, 357:1716-1730. 10.1056/NEJMoa075392, 17890232.
4. Miyashita Y, Nishimura R, Nemoto M, Matsudaira T, Kurata H, Yokota T, Yokota K, Tojo K, Utsunomiya K, Tajima N. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008, 7:16. 10.1186/1475-2840-7-16, 2442047, 18507868.
5. Hirao K, Arai K, Yamauchi M, Takagi H, Kobayashi M, . Japan Diabetes Clinical Data Management Study Group Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008, 79:171-6. 10.1016/j.diabres.2007.08.011, 17919762, Japan Diabetes Clinical Data Management Study Group.
6. Yoshino G, Tominagab M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima M, Sanke T, Oikawa S, Honda K, Tachikawa T. The Test Meal A: A Pilot Model for the International Standard of Test Meal for an Assessment of Both Postprandial Hyperglycemia and Hyperlipidemia. J Jpn Diabetes Soc 2006, 49:361-371.
7. Boyne MS, Silver DM, Kaplan J, Saudek CD. Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003, 52:2790-4. 10.2337/diabetes.52.11.2790, 14578298.
8. SPSS. , http://www.spss.co.jp/
9. UMIN Clinical Trials Registry. , http://www.umin.ac.jp/ctr/index-j.htm
10. Rosenstock J, Ahmann AJ, Colon G, Scism-Bacon J, Jiang H, Martin S. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008, 31:20-5. 10.2337/dc07-1122, 17934150.
11. Hirao K, Maeda H, Urata S, Takisawa Y, Hirao S, Sasako T, Sasaki T. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. Clin Ther 2007, 29:927-34. 10.1016/j.clinthera.2007.05.017, 17697911.
12. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002, 24:530-9. 10.1016/S0149-2918(02)85129-3, 12017398.
13. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002, 19:393-9. 10.1046/j.1464-5491.2002.00733.x, 12027927.